Insulin dose and cardiovascular mortality in the ACCORD trial

Diabetes Care

Volumn 38, Issue 11, 2015, Pages 2000-2008

  Siraj, Elias S ^a   Rubin, Daniel J ^a   Riddle, Matthew C ^b   Miller, Michael E ^c   Hsu, Fang Chi ^c   Ismail Beigi, Faramarz ^d   Chen, Shyh Huei ^c   Ambrosius, Walter T ^c   Thomas, Abraham ^e   Bestermann, William ^f   Buse, John B ^g   Genuth, Saul ^d   Joyce, Carol ^h   Kovacs, Christopher S ^h   O'connor, Patrick J ⁱ   Sigal, Ronald J ^j   Solomon, Sol ^k  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HENRY FORD HOSPITAL   (United States)

^f Holston Medical Group   (United States)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^h Health Sciences Centre St John's   (Canada)

ⁱ HEALTHPARTNERS INSTITUTE   (United States)

^j UNIVERSITY OF CALGARY   (Canada)

^k UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

ADULT; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; WEIGHT CHANGE; AGED; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; HYPOGLYCEMIA; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ADULT; AGED; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 84962439220     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-0598     Document Type: Article

References (25)

1. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589.
2. Riddle MC. Counterpoint: Intensive glucose control and mortality in ACCORD-still looking for clues. Diabetes Care 2010;33:2722-2724.
3. Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA(1c) in people with type 2 diabetes: A retrospective cohort study. Lancet 2010;375:481-489.
4. Gerstein HC, Miller ME, Byington RP, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559.
5. ACCORD Study Group, Gerstein HC, Miller ME, Genuth S, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011;364:818-828.
6. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572.
7. Duckworth W, Abraira C, Moritz T, et al.; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139.
8. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 2008;358:2630-2633.
9. Hirsch IB. Piecing the puzzle together: ACCORDing to whom? J Clin Endocrinol Metab 2008;93:1161-1163.
10. Skyler JS, Bergenstal R, Bonow RO, et al.; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009;32:187-192.
11. Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010;340:b4909.
12. Riddle MC, Ambrosius WT, Brillon DJ, et al.; Action to Control Cardiovascular Risk in Diabetes Investigators. Epidemiologic relationships between A1C and all-causemortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010;33:983-990.
13. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865.
14. Dosluoglu HH, Lall P, Nader ND, Harris LM, Dryjski ML. Insulin use is associated with poor limb salvage and survival in diabetic patients with chronic limb ischemia. J Vasc Surg 2010; 51:1178-1189; discussion 1188-1189.
15. Gamble JM, Simpson SH, Eurich DT, Majumdar SR, Johnson JA. Insulin use and increased risk of mortality in type 2 diabetes: A cohort study. Diabetes Obes Metab 2010;12:47-53.
16. Pyörälä M, Miettinen H, Laakso M, Pyörälä K. Plasma insulin and all-cause, cardiovascular, and noncardiovascular mortality: The 22-year follow-up results of the Helsinki Policemen Study. Diabetes Care 2000;23:1097-1102.
17. Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocr Rev 2007;28:463-491.
18. Rensing KL, Reuwer AQ, Arsenault BJ, et al. Reducing cardiovascular disease risk in patients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much of a good thing? Diabetes Obes Metab 2011;13:1073-1087.
19. Goff DC Jr, Gerstein HC, Ginsberg HN, et al.; ACCORD Study Group. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99(Suppl.):4i-20i.
20. Buse JB, Bigger JT, Byington RP, et al.; ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007;99(Suppl.):21i-33i.
21. Gerstein HC, Riddle MC, Kendall DM, et al.; ACCORD Study Group. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99(Suppl.):34i-43i.
22. Gerstein HC, Bosch J, Dagenais GR, et al.; ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319-328.
23. Nathan DM, Cleary PA, Backlund JY, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653.
24. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
25. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine-reporting of subgroup analyses in clinical trials. N Engl J Med 2007;357:2189-2194.